HLX 1502
Alternative Names: HLX-1502Latest Information Update: 06 Aug 2024
At a glance
- Originator Healx; The Childrens Tumor Foundation
- Developer Healx
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurofibromatosis 1
Most Recent Events
- 06 Aug 2024 Phase-I clinical trials in Neurofibromatosis 1 (unspecified route) (Healx pipeline, August 2024)
- 01 Aug 2024 Healx plans a phase II INSPIRE-NF1 trial in Neurofibromatosis 1 (In adolescents, In adults, In the elderly) (PO) in October 2024 (NCT06541847)
- 01 Aug 2024 HLX 1502 receives Rare Pediatric Disease Designation to for the treatment of neurofibromatosis 1